You are here

Award Data

For best search results, use the search terms first and then apply the filters
Reset

The Award database is continually updated throughout the year. As a result, data for FY24 is not expected to be complete until March, 2025.

Download all SBIR.gov award data either with award abstracts (290MB) or without award abstracts (65MB). A data dictionary and additional information is located on the Data Resource Page. Files are refreshed monthly.

The SBIR.gov award data files now contain the required fields to calculate award timeliness for individual awards or for an agency or branch. Additional information on calculating award timeliness is available on the Data Resource Page.

  1. Creating a predictive vascular system for early development

    SBC: HemoShear Therapeutics, LLC            Topic: NHLBI

    DESCRIPTION (provided by applicant): The frequent inability of in vitro assays and animal models to accurately predict human response to a new drug candidate results in costly drug development failures. HemoShear has developed a platform technology for biodiscovery and drug pharmacology screening that replicates human biological function in healthy and diseased organ systems by applying human-deri ...

    SBIR Phase II 2011 Department of Health and Human ServicesNational Institutes of Health
  2. TDP-43 aggregation inhibitors for the treatment of ALS

    SBC: Aquinnah Pharmaceuticals Inc.            Topic: 105

    Abstract Amyotrophic Lateral SclerosisALSis a universally fatal neurodegenerative disease that afflicts overout of everyindividualsProtein aggregation has been implicated as a primary driving force in ALS and multiple other neurodegenerative illnessesTDPis the principle component of the protein aggregates in ALSand TDPalso stands out as the only genetically defined ALS mutant gene that is also the ...

    SBIR Phase II 2018 Department of Health and Human ServicesNational Institutes of Health
  3. Novel Antithrombotic Diadenosine Tetraphosphate Analogs

    SBC: GLSynthesis Inc.            Topic: NCATS

    DESCRIPTION: Undesired platelet activation can be result of many common pathologies or interventions. Arterial thrombosis and the acute ischemic events that follow, such as myocardial infarction and stroke, are among the leading causes of death, incapacitation, and rising health care costs in the developed world. Therefore antiplatelet drugs have significant market share and clinical importance, ...

    SBIR Phase II 2013 Department of Health and Human ServicesNational Institutes of Health
  4. Novel Antithrombotic Diadenosine Tetraphosphate Analogs

    SBC: GLSynthesis Inc.            Topic: 100

    DESCRIPTION Undesired platelet activation can be result of many common pathologies or interventions Arterial thrombosis and the acute ischemic events that follow such as myocardial infarction and stroke are among the leading causes of death incapacitation and rising health care costs in the developed world Therefore antiplatelet drugs have significant market share and clinical importance ...

    SBIR Phase II 2013 Department of Health and Human ServicesNational Institutes of Health
  5. Supportive Clinical Trial Tasks for Nanotechnology-Based Treatment of Oral Cancer

    SBC: PRIVO TECHNOLOGIES, LLC            Topic: NCI

    Preceding Award: NCI Award 1R44CA192875-02 Project Summary: According to the Oral Cancer Foundation, about 50,000 people in the US will be newly diagnosed with oral cancer (OC) in 2017, causing 9,700 deaths[1]. OC is a severely neglected orphan disease with a lack of significant treatment advances in 4 decades[1]. Historically, OC has been present in heavy smokers and drinkers. However, more recen ...

    SBIR Phase II 2018 Department of Health and Human ServicesNational Institutes of Health
  6. Microfabricated Implantable Flowmeter for CSF Shunts Phase II

    SBC: VIVONICS INC            Topic: NINDS

    DESCRIPTION (provided by applicant): An implantable wireless flow sensor system has been under development that would enable measurement of the flow of cerebrospinal fluid (CSF) through the ventriculoperitoneal (VP) shunt, currently used to treat hydrocephalus patients. CSF flow is a key indicator of shunt function, and there is currently no way to measure it in situ, resulting in the absence ...

    SBIR Phase II 2011 Department of Health and Human ServicesNational Institutes of Health
  7. Type III Secretion Inhibitors for Anti-Infective Therapy

    SBC: MICROBIOTIX, INC.            Topic: NIAID

    DESCRIPTION (provided by applicant): Pseudomonas aeruginosa infection is the leading cause of hospital-acquired pneumonia in patients undergoing mechanical ventilation. Current antibiotic treatments exhibit failure rates as high as 18%, even when the organism is susceptible to the antibiotic being administered. The goal of this project is to address this critical medical need by identifying specif ...

    SBIR Phase II 2011 Department of Health and Human ServicesNational Institutes of Health
  8. Narrow-spectrum Agents Acting against Helicobacter pylori

    SBC: ARIETIS CORPORATION            Topic: NIAID

    DESCRIPTION provided by applicant The goal of this project is to develop a therapeutic acting specifically against Helicobacter pylori the causative agent of peptic ulcer and gastric carcinoma Roughly every other person carries the pathogen and there are an estimated cases annually of active infection in the US The currently used triple therapy is a combination of a proton pump inhibitor and broad ...

    SBIR Phase II 2013 Department of Health and Human ServicesNational Institutes of Health
  9. Novel anti-viral agents to treat influenza

    SBC: ALEXANDER BIODISCOVERIES, LLC            Topic: NIAID

    DESCRIPTION provided by applicant Yearly influenza epidemics affect about of the worldandapos s population and estimates of annual mortality range from including approximately deaths and hospitalizations in the United States In addition the likelihood of a severe pandemic caused by a newly emergent strain of influenza virus is very high given that three such pandemics were recorded in the th centu ...

    SBIR Phase II 2013 Department of Health and Human ServicesNational Institutes of Health
  10. SBIR TOPIC 096:Novel Biodegradable Stents for Neonatal Aortic Coarctation

    SBC: Lyra Therapeutics, Inc.            Topic: NHLBI

    Aortic coarctation is a common congenital heart condition that is usually recognized during the neonatal period early after birth The usual treatment is open surgery Non surgical catheter based stent therapy is not available to treat neonatal aortic coarctation because children outgrow commercially available metallic stents Absorbable stents might revolutionize the treatment of aortic coarctation ...

    SBIR Phase II 2018 Department of Health and Human ServicesNational Institutes of Health
US Flag An Official Website of the United States Government